Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Variability in Tam metabolism and clearance have been reported based on age, dosage, treatment duration, genetic differences, sex, and other factors, leading to different half-lives and potencies of the metabolites.19,20,21”
From Specificity and efficiency of tamoxifen-mediated Cre induction is equivalent regardless of age (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Research works printed but not linked: 109
- Ahern, 2010, Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue, Clinical Epidemiology, 2, 241, 10.2147/CLEP.S13811 · doi:10.2147/clep.s13811
- Ahern, 2011, Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors, Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 20, 1937, 10.1158/1055-9965.EPI-11-0419 · doi:10.1158/1055-9965.epi-11-0419
- Ahern, 2017, Cytochrome P-450 2D6 (CYP2D6) genotype and breast cancer recurrence in tamoxifen-treated patients: Evaluating the importance of loss of heterozygosity, American Journal of Epidemiology, 185, 75, 10.1093/aje/kww178 · DOI
- Amiri-Kordestani, 2012, Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies, Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 15, 50, 10.1016/j.drup.2012.02.002 · DOI · Paper page
- Argalacsova, 2017, Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients, Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology, 22, 1217
- Baum, 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 · DOI · Paper page
- Baurley, 2010, Discovery of complex pathways from observational data, Statistics in Medicine, 29, 1998, 10.1002/sim.3962 · DOI
- Berry, 2013, CYP2D6 genotyping and the use of tamoxifen in breast cancer, Journal of the National Cancer Institute, 105, 1267, 10.1093/jnci/djt221 · doi:10.1093/jnci/djt221
- Berry, 2014, Response, Journal of the National Cancer Institute, 106, 10.1093/jnci/dju065 · doi:10.1093/jnci/dju065
- Biglia, 2005, Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors, Maturitas, 52, 78, 10.1016/j.maturitas.2005.01.001 · DOI
- Borges, 2010, Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients, Journal of Clinical Pharmacology, 50, 450, 10.1177/0091270009359182 · doi:10.1177/0091270009359182
- Borges, 2006, Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment, Clinical Pharmacology and Therapeutics, 80, 61, 10.1016/j.clpt.2006.03.013 · DOI · Paper page
- Burger, 2008, Cycle and hormone changes during perimenopause: The key role of ovarian function, Menopause (New York, N.Y.), 15, 603, 10.1097/gme.0b013e318174ea4d · DOI · Paper page
- Buzdar, 2002, Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer, Breast Cancer Research and Treatment, 73, 161, 10.1023/A:1015229630260 · DOI
- Buzdar, 2006, Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial, The Lancet Oncology, 7, 633, 10.1016/S1470-2045(06)70767-7 · DOI · Paper page
- Buzdar, 1988, Phase II evaluation of Ly156758 in metastatic breast cancer, Oncology, 45, 344, 10.1159/000226637 · doi:10.1159/000226637
- Chamnanphon, 2013, Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen, Pharmacogenomics and Personalized Medicine, 6, 37
- Chubak, 2016, Breast cancer recurrence in relation to antidepressant use, Cancer Causes & Control: CCC, 27, 125, 10.1007/s10552-015-0689-y · DOI
- Cronin-Fenton, 2013, Metabolism and transport of tamoxifen in relation to its effectiveness: New perspectives on an ongoing controversy, Future Oncology, 10, 107, 10.2217/fon.13.168 · DOI
- Cronin-Fenton, 2010, Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: Risk of breast cancer recurrence and mortality, Future Oncology, 6, 877, 10.2217/fon.10.65 · DOI
- Davies, 2013, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 381, 805, 10.1016/S0140-6736(12)61963-1 · DOI · Paper page
- De Ameida Melo, 2016, CYP2D6 gene polymorphisms in brazilian patients with breast cancer treated with adjuvant tamoxifen and its association with disease recurrence, Biomedical Reports, 5, 574, 10.3892/br.2016.771 · doi:10.3892/br.2016.771
- Deitcher, 2004, The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: A systematic review, Cancer, 101, 439, 10.1002/cncr.20347 · DOI · Paper page
- Demissie, 2001, Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women, Journal of Clinical Oncology, 19, 322, 10.1200/JCO.2001.19.2.322 · DOI · Paper page
- Deng, 2001, Population admixture may appear to mask, change or reverse genetic effects of genes underlying complex traits, Genetics, 159, 1319, 10.1093/genetics/159.3.1319 · DOI
- Deshmane, 2007, Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25, 4967, 10.1200/JCO.2006.09.5992 · DOI
- Dezentje, 2015, CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects, Breast Cancer Research and Treatment, 153, 583, 10.1007/s10549-015-3562-5 · DOI
- Dezentje, 2013, CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial, Breast Cancer Research and Treatment, 140, 363, 10.1007/s10549-013-2619-6 · DOI
- Donneyong, 2016, Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: Multi-database cohort study, BMJ (Clinical Research Ed.), 354, i5014
- 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials, Lancet, 365, 1687
- Ellsworth, 2003, High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer, Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 12, 915
- Fan, 2009, Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: Evidence from in vitro breast cancer cell models, Endocrinology, 150, 2036, 10.1210/en.2008-1195 · DOI
- Fisher, 2005, Tamoxifen for the prevention of breast cancer: Current status of the national surgical adjuvant breast and bowel project P-1 study, The Journal of the National Cancer Institute, 97, 1652, 10.1093/jnci/dji372 · DOI · Paper page
- Freour, 2017, Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy, European Journal of Cancer (Oxford, England: 1990), 74, 1, 10.1016/j.ejca.2016.12.008 · DOI
- Gaedigk, 2013, Complexities of CYP2D6 gene analysis and interpretation, International Review of Psychiatry (Abingdon, England), 25, 534, 10.3109/09540261.2013.825581 · DOI · Paper page
- Gjerde, 2008, Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism, Annals of Oncology, 19, 56, 10.1093/annonc/mdm434 · doi:10.1093/annonc/mdm434
- Goetz, 2008, Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response, Clinical Pharmacology and Therapeutics, 83, 160, 10.1038/sj.clpt.6100367 · DOI · Paper page
- Goetz, 2005, Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes, Journal of Clinical Oncology, 23, 9312, 10.1200/JCO.2005.03.3266 · DOI · Paper page
- Goetz, 2017, First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35, 3391, 10.1200/JCO.2017.73.3246 · DOI
- Goetz, 2014, Loss of heterozygosity at the CYP2D6 locus in breast cancer: Implications for germline pharmacogenetic studies, Journal of the National Cancer Institute, 107, 10.1093/jnci/dju401 · doi:10.1093/jnci/dju401
- Gradishar, 2000, Effects of high dose raloxifene in selected patients with advanced breast carcinoma, Cancer, 88, 2047, 10.1002/(SICI)1097-0142(20000501)88:9<2047::AID-CNCR10>3.0.CO;2-E · doi:10.1002/(sici)1097-0142(20000501)88:9<2047::aid-cncr10>3.0.co;2-e
- Gray, R. G., Rea, D. W., Handley, K., Marshall, A., Pritchard, M. G., Perry, P.,… (2008). aTTom (adjuvant tamoxifen—To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—Preliminary results. [Abstract]. Journal of Clinical Oncology (Meeting Abstracts), 26 513. · DOI
- Haque, 2015, Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors, Journal of the National Cancer Institute, 108, 10.1093/jnci/djv337 · DOI · Paper page
- Hayes, 1995, Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 13, 2556, 10.1200/JCO.1995.13.10.2556 · DOI · Paper page
- Helland, 2017, Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients, Breast Cancer Research: BCR, 19, 125, 10.1186/s13058-017-0916-4 · DOI
- Henry, 2009, Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort, Breast Cancer Research and Treatment, 117, 571, 10.1007/s10549-009-0309-1 · DOI
- Hertz, 2017, CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: Results from a population-based study, Breast Cancer Research and Treatment, 166, 277, 10.1007/s10549-017-4400-8 · DOI
- Hicks, 2013, Beta-blocker usage and colorectal cancer mortality: A nested case-control study in the UK clinical practice research datalink cohort, Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 24, 3100, 10.1093/annonc/mdt381 · DOI
- Hicks, 2014, Challenges in CYP2D6 phenotype assignment from genotype data: A critical assessment and call for standardization, Current Drug Metabolism, 15, 218, 10.2174/1389200215666140202215316 · doi:10.2174/1389200215666140202215316
- Hirano, 2001, Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 7, 876
- Hu, 2016, Functional characterization of 22 novel CYP2D6 variants for the metabolism of tamoxifen, The Journal of Pharmacy and Pharmacology, 68, 819, 10.1111/jphp.12556 · DOI · Paper page
- International Breast Cancer Study Group, 2004, Toremifene and tamoxifen are equally effective for early-stage breast cancer: First results of international breast cancer study group trials 12-93 and 14-93, Annals of Oncology: Official Journal of the European Society for Medical Oncology, 15, 1749, 10.1093/annonc/mdh463 · DOI
- Iusuf, 2011, P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration, The Journal of Pharmacology and Experimental Therapeutics, 337, 710, 10.1124/jpet.110.178301 · DOI
- Jin, 2005, CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment, The Journal of the National Cancer Institute, 97, 30, 10.1093/jnci/dji005 · DOI · Paper page
- Johansson, 2016, A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen, Breast Cancer Research and Treatment, 159, 97, 10.1007/s10549-016-3932-7 · doi:10.1007/s10549-016-3932-7
- Johnson, 2015, Loss of heterozygosity at the CYP2D6 locus in breast cancer: Implications for tamoxifen pharmacogenetic studies, Journal of the National Cancer Institute, 107, 10.1093/jnci/dju437 · doi:10.1093/jnci/dju437
- Johnson, 2004, Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen, Breast Cancer Research and Treatment, 85, 151, 10.1023/B:BREA.0000025406.31193.e8 · DOI · Paper page
- Jordan, 2008, Tamoxifen: Catalyst for the change to targeted therapy, European Journal of Cancer (Oxford, England: 1990), 44, 30, 10.1016/j.ejca.2007.11.002 · DOI · Paper page
- Jordan, 1977, A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity, The Journal of Endocrinology, 75, 305, 10.1677/joe.0.0750305 · DOI · Paper page
- Jordan, 2011, The St. Gallen prize lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: Consequences and opportunities, Breast (Edinburgh, Scotland), 20, S1
- 1996, Journal of the National Cancer Institute, 88, 1543, 10.1093/jnci/88.21.1543 · DOI · Paper page
- Juurlink, 2016, Revisiting the drug interaction between tamoxifen and SSRI antidepressants, BMJ (Clinical Research Ed.), 354, i5309
- Karle, 2013, Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer, Breast Cancer Research and Treatment, 139, 553, 10.1007/s10549-013-2565-3 · doi:10.1007/s10549-013-2565-3
- Kiyotani, 2010, Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients, Journal of Clinical Oncology, 28, 1287, 10.1200/JCO.2009.25.7246 · DOI · Paper page
- Kiyotani, 2008, Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy, Cancer Science, 99, 995, 10.1111/j.1349-7006.2008.00780.x · doi:10.1111/j.1349-7006.2008.00780.x
- Lai, 2012, Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability—Considerations for drug development, Expert Opinion on Drug Metabolism & Toxicology, 8, 723, 10.1517/17425255.2012.678048 · DOI
- Lash, 2008, Comment on 'impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy', Cancer Science, 99, 1706, 10.1111/j.1349-7006.2008.00864.x · doi:10.1111/j.1349-7006.2008.00864.x
- Lash, 2009, Immortal person-time in studies of cancer outcomes, Journal of Clinical Oncology, 27, e55, 10.1200/JCO.2009.24.1877 · DOI
- Lash, 2011, CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark, The Journal of the National Cancer Institute, 103, 489, 10.1093/jnci/djr010 · DOI
- Lash, 2009, Genotype-guided tamoxifen therapy: Time to pause for reflection?, The Lancet Oncology, 10, 825, 10.1016/S1470-2045(09)70030-0 · DOI
- Lazarus, 2009, Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen, The Annals of the New York Academy of Sciences, 1155, 99, 10.1111/j.1749-6632.2009.04114.x · DOI
- Lei, 2016, Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population, American Journal of Translational Research, 8, 3585
- Leslie, 2005, Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicology and Applied Pharmacology, 204, 216, 10.1016/j.taap.2004.10.012 · DOI · Paper page
- Lien, 1988, Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile, Cancer Research, 48, 2304
- Lim, 2005, Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen, Cancer Chemotherapy and Pharmacology, 55, 471, 10.1007/s00280-004-0926-7 · DOI · Paper page
- Madlensky, 2011, Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes, Clinical Pharmacology and Therapeutics, 89, 718, 10.1038/clpt.2011.32 · DOI · Paper page
- Marcath, 2017, Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment, Pharmacogenetics and Genomics, 27, 402, 10.1097/FPC.0000000000000311 · DOI
- Markkula, 2014, No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients, Acta Oncologica (Stockholm, Sweden), 53, 195, 10.3109/0284186X.2013.840739 · doi:10.3109/0284186x.2013.840739
- Martins, 2014, Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in Sao Luis, Brazil, and its association with prognostic factors and disease-free survival, Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas e Biologicas, 47, 1008, 10.1590/1414-431X20143761 · doi:10.1590/1414-431x20143761
- Mwinyi, 2014, Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy, Cancer Chemotherapy and Pharmacology, 73, 1181, 10.1007/s00280-014-2453-5 · doi:10.1007/s00280-014-2453-5
- Pharoah, 2012, Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial and re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients, Journal of the National Cancer Institute, 104, 1263, 10.1093/jnci/djs312 · DOI
- Powers, 2016, Multigene and drug interaction approach for tamoxifen metabolite patterns reveals possible involvement of CYP2C9, CYP2C19, and ABCB1, Journal of Clinical Pharmacology, 56, 1570, 10.1002/jcph.771 · DOI
- Rae, 2003, Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples, Pharmacogenetics, 13, 501, 10.1097/00008571-200308000-00008 · DOI
- Rae, 2012, CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients, Journal of the National Cancer Institute, 104, 452, 10.1093/jnci/djs126 · DOI · Paper page
- Rae, 2013, Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA, Journal of the National Cancer Institute, 105, 1332, 10.1093/jnci/djt204 · doi:10.1093/jnci/djt204
- Reed, 2011, The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment, Pharmacogenomics, 12, 1465, 10.2217/pgs.11.84 · DOI
- Regan, 2012, CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial, Journal of the National Cancer Institute, 104, 441, 10.1093/jnci/djs125 · DOI · Paper page
- Saladores, 2015, Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer, The Pharmacogenomics Journal, 15, 84, 10.1038/tpj.2014.34 · DOI · Paper page
- Sanchez Spitman, 2017, Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism, European Journal of Clinical Pharmacology, 73, 1589, 10.1007/s00228-017-2323-2 · DOI
- Sanchez-Spitman, 2017, The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen, Pharmacogenomics, 18, 1125, 10.2217/pgs-2017-0080 · doi:10.2217/pgs-2017-0080
- Schneider, 2006, Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes, Breast Cancer Research and Treatment, 96, 209, 10.1007/s10549-005-9003-0 · doi:10.1007/s10549-005-9003-0
- Sensorn, 2013, Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of thai breast cancer patients treated with tamoxifen, Pharmacogenomics and Personalized Medicine, 6, 93, 10.2147/PGPM.S44006 · DOI
- Sheng, 1996, Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas, British Journal of Cancer, 73, 144, 10.1038/bjc.1996.27 · DOI
- Sherman, 1979, Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women, The Journal of Clinical Investigation, 64, 398, 10.1172/JCI109475 · DOI
- Sideras, 2010, Coprescription of tamoxifen and medications that inhibit CYP2D6, Journal of Clinical Oncology, 28, 2768, 10.1200/JCO.2009.23.8931 · DOI · Paper page
- Stanton, 2012, Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial, Journal of the National Cancer Institute, 104, 1265, 10.1093/jnci/djs305 · DOI
- Stearns, 2003, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine, The Journal of the National Cancer Institute, 95, 1758, 10.1093/jnci/djg108 · DOI · Paper page
- Sukasem, 2012, Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: A microarray-based study in Thailand, Asian Pacific Journal of Cancer Prevention: APJCP, 13, 4549, 10.7314/APJCP.2012.13.9.4549 · doi:10.7314/apjcp.2012.13.9.4549
- Swerdlow, 2005, Tamoxifen treatment for breast cancer and risk of endometrial cancer: A case-control study, The Journal of the National Cancer Institute, 97, 375, 10.1093/jnci/dji057 · DOI · Paper page
- Teft, 2011, Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1), Drug Metabolism and Disposition: The Biological Fate of Chemicals, 39, 558, 10.1124/dmd.110.036160 · DOI
- Teh, 2012, The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1, The AAPS Journal, 14, 52, 10.1208/s12248-011-9313-6 · DOI
- Thompson, 2011, Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy, Breast Cancer Research and Treatment, 125, 279, 10.1007/s10549-010-1139-x · DOI
- Valachis, 2016, Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: A population-based study, Breast Cancer Research and Treatment, 159, 293, 10.1007/s10549-016-3928-3 · DOI
- Wheeler, 2013, Cancer pharmacogenomics: Strategies and challenges, Nature Reviews. Genetics, 14, 23, 10.1038/nrg3352 · DOI · Paper page
- Xie, 2006, Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer, Carcinogenesis, 27, 307, 10.1093/carcin/bgi215 · doi:10.1093/carcin/bgi215
- Xu, 2008, Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment, Annals of Oncology, 19, 1423, 10.1093/annonc/mdn155 · doi:10.1093/annonc/mdn155
- Yazdi, 2015, CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients, Asian Pacific Journal of Cancer Prevention: APJCP, 16, 6783, 10.7314/APJCP.2015.16.15.6783 · doi:10.7314/apjcp.2015.16.15.6783
- Zanger, 2004, Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry, Naunyn-Schmiedebergs Archives of Pharmacology, 369, 23, 10.1007/s00210-003-0832-2 · DOI · Paper page
- Zhang, 2015, Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy, Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 21, 563, 10.12659/MSM.893473 · DOI
Cited by
Specificity and efficiency of tamoxifen-mediated Cre induction is equivalent regardless of age
Kellogg, C. M., Pham, K., Ko, S., Cox, J. E. J., Machalinski, A. H., Stout, M. B., Sharpe, A. L., Beckstead, M. J., Chucair-Elliott, A. J., Ocañas, S. R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108413 · Cited by 10
Metadata
- Authors
- Cronin-Fenton, D. P., & Damkier, P.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2018
- Pages
- 65-91
- ISSN
- 1054-3589
- Cited by
- 42
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. https://app.cochat.ai/papers/10.1016/bs.apha.2018.03.001
- The paper
- Cronin-Fenton, D. P., & Damkier, P. (2018). Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. Advances in Pharmacology. https://doi.org/10.1016/bs.apha.2018.03.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.